Stakeholder Insight: Hepatitis in China

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-12-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Hepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally. HBV vaccination, together with HBV and HCV screening have helped to reduce transmission, but continued transmission from mother to child (for HBV) and transmission via blood transfusions (HCV) means that HBV and HCV are likely to remain a problem.


Scope

  • Analysis of the current dynamics of the Chinese hepatitis market through primary research data from 176 physicians, supported by key opinion leaders
  • Identification of drivers and resistors of the Chinese hepatitis market, and how the Chinese healthcare system impacts these market-shaping factors
  • Examination of key hepatitis drug regimens for hepatitis in China, and factors affecting prescription trends underlying these regimens
  • Assessment of the differences between China and the 7 major markets in terms of HBV and HCV transmission and diagnosis


    • Report Highlights
    Datamonitor physician research indicated that HBV incidence is decreasing in China. In contrast to the seven major markets, where most patients acquire HBV sexually, perinatal transmission is the dominant HBV transmission route, which impacts on HBV disease progression and effectiveness of drug therapy.

    Chinese physicians believe that HCV incidence may be increasing in China. Blood transfusion is though to be the dominant HCV transmission route in China, while in the seven major markets, HCV is mainly acquired through intravenous drug use.

    Chinese physicians do not consider any HBV therapy a gold-standard, although lamivudine is the most prescribed first-line therapy, while adefovir is the most prescribed second-line therapy. While treatment choice is more limited for HCV, the Chinese HCV market is highly fragmented, with treatment differing significantly between regions.


    Reasons to Purchase

  • Review the clinical and commercial factors shaping the uptake of hepatitis products in China, and the opportunities and threats facing the market
  • Gain insight into HBV and HCV prevalence, transmission and coinfection in China
  • Evaluate unmet needs in China's hepatitis market and capitalize on these opportunities to develop commercial strategies to increase market penetration

    • Table of Contents

    Other users found this report page using the following search terms: hepatitis china chinese

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.